TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18987368

Group type: EXPERIMENTAL
Intervention: 300 microg of testosterone per day
Number of subjects: 814

Group type: EXPERIMENTAL
Intervention: 150 microg of testosterone per day
Number of subjects: 814

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 814
Study: 15694877

Group type: EXPERIMENTAL
Intervention: Electronic daily diary assessment of pain-related variables
Number of subjects: 71
Study: 12752557

Group type: EXPERIMENTAL
Intervention: Hyperbaric hyperoxia (HBO) exposure for O2 divers (6 hours, PiO2 varied from 1.15 to 2.7 ATA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Hyperbaric hyperoxia (HBO) exposure for air divers (2 hours, PiO2 constant at 1.15 ATA)
Number of subjects: 17
Study: 10586979

Group type: EXPERIMENTAL
Intervention: Dietary counseling and home glucose monitoring (HBGM)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard euglycemic diet and home glucose monitoring (HBGM)
Number of subjects: 83
Study: 8901368

Group type: EXPERIMENTAL
Intervention: Visual analogue scale without hashmarks
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Visual analogue scale with hashmarks
Number of subjects: 213

Group type: COMPARATOR
Intervention: Descriptive terms ('mildly', 'moderately', 'severely')
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Errors of order
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Descriptive terms with numerical values
Number of subjects: 213
Study: 1876742

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 0.05 mg of fentanyl
Number of subjects: 204

Group type: COMPARATOR
Intervention: 0.25% bupivacaine alone
Number of subjects: 204
Study: 7048881

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 62

Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 62
Study: 31518627

Group type: COMPARATOR
Intervention: Gender (Women)
Number of subjects: 3213

Group type: COMPARATOR
Intervention: Presence of a walking path
Number of subjects: 3213
Study: 28177715

Group type: EXPERIMENTAL
Intervention: CHO-S
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CHO-F
Number of subjects: 25

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 25
Study: 25199441

Group type: EXPERIMENTAL
Intervention: Apical-touch fitting approach
Number of subjects: 31

Group type: COMPARATOR
Intervention: Three-point-touch fitting approach
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both fitting approaches
Number of subjects: 31
Study: 24060194

Group type: EXPERIMENTAL
Intervention: Parent-enhanced CBT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Individual CBT
Number of subjects: 50
Study: 21532072

Group type: EXPERIMENTAL
Intervention: Systematic implementation of behavioral interventions including trauma-informed care training, changes to unit rules and language, changes to the physical characteristics of the therapeutic environment, and involvement of patients in treatment planning.
Number of subjects: 89783

Group type: EXPERIMENTAL
Intervention: Changes to the physical environment during the intervention rollout period.
Number of subjects: 89783
Study: 18971549

Group type: EXPERIMENTAL
Intervention: Losartan (12.5 mg/d)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (antiplatelet agents)
Number of subjects: 18
Study: 16155076

Group type: EXPERIMENTAL
Intervention: rosiglitazone 8 mg daily for 12 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: rosiglitazone 2 mg daily for 12 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg daily for 12 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: rosiglitazone
Number of subjects: 42
Study: 14640835

Group type: EXPERIMENTAL
Intervention: Familiarized with repetitions of 2 words and tested on orientation times to 4 passages (2 familiarized words)
Number of subjects: 0
Study: 10849267

Group type: COMPARATOR
Intervention: Interferon-a2a (IFN) alone
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of Interferon-a2a (IFN) with oral ganciclovir
Number of subjects: 40
Study: 9089855

Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms/mL with lidocaine 1.5%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Epinephrine 5 micrograms/mL with lidocaine 1.5%
Number of subjects: 40
Study: 8260124

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zolpidem 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Codeine phosphate 60 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 2994451

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30600521

Group type: EXPERIMENTAL
Intervention: Thula Baba Box (TBB) and monthly Community Health Worker (CHW) visits
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard clinical practice (Control)
Number of subjects: 72
Study: 29970875

Group type: EXPERIMENTAL
Intervention: Breviscapine (40 mg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 28708702

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic (IH) protocol (n = 11)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (normoxia; n = 8)
Number of subjects: 19
Study: 26307245

Group type: EXPERIMENTAL
Intervention: Person-centered model of care
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Barriers and enablers for the person-centered model
Number of subjects: 131
Study: 24274215

Group type: EXPERIMENTAL
Intervention: Blakesley forceps
Number of subjects: 311

Group type: COMPARATOR
Intervention: Microdebrider
Number of subjects: 311
Study: 21950300

Group type: EXPERIMENTAL
Intervention: Oral Methotrexate (MTX) 2.5 mg daily for 4 weeks
Number of subjects: 101

Group type: COMPARATOR
Intervention: Oral Methotrexate (MTX) weekly (not specified dosage)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Oral Methotrexate (MTX) daily
Number of subjects: 101

Group type: COMPARATOR
Intervention: Oral Methotrexate (MTX) weekly
Number of subjects: 101
Study: 18449064

Group type: EXPERIMENTAL
Intervention: 0.25% chlorhexidine solution
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 0.50% chlorhexidine solution
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: 1.00% chlorhexidine solution
Number of subjects: 286

Group type: COMPARATOR
Intervention: Control (no chlorhexidine)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Heel prick blood sample
Number of subjects: 286
Study: 16540246

Group type: EXPERIMENTAL
Intervention: Adequate antipsychotic treatment
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control groups (healthy controls, cannabis controls, multiple substance controls)
Number of subjects: 114
Study: 12488289

Group type: EXPERIMENTAL
Intervention: Single 6 mg subcutaneous injection of pegfilgrastim
Number of subjects: 157

Group type: COMPARATOR
Intervention: Daily 5 mg/kg subcutaneous injections of filgrastim
Number of subjects: 157
Study: 11403727

Group type: EXPERIMENTAL
Intervention: Bupropion SR 100 mg/day
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg/day
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/day
Number of subjects: 519

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Bupropion SR
Number of subjects: 519
Study: 9517526

Group type: EXPERIMENTAL
Intervention: rice ORS containing 50 g/l rice and 70 mmol/l Na+
Number of subjects: 123

Group type: COMPARATOR
Intervention: WHO ORS
Number of subjects: 123

Group type: COMPARATOR
Intervention: ORS containing 70 mmol/l Na+ and 16.2 g/l glucose
Number of subjects: 123

Group type: COMPARATOR
Intervention: rice ORS containing 50 g/l rice and 90 mmol/l Na+
Number of subjects: 123
Study: 8277035

Group type: EXPERIMENTAL
Intervention: 0.1% tretinoin cream
Number of subjects: 45

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 45
Study: 3140683

Group type: EXPERIMENTAL
Intervention: Metrifonate (10 mg/kg x 3 doses)
Number of subjects: 2628

Group type: COMPARATOR
Intervention: Praziquantel (40 mg/kg x 1 dose)
Number of subjects: 2628

Group type: EXPERIMENTAL
Intervention: Metrifonate
Number of subjects: 2628

Group type: COMPARATOR
Intervention: Praziquantel
Number of subjects: 2628

Group type: EXPERIMENTAL
Intervention: Metrifonate and Praziquantel
Number of subjects: 2628
Study: 29059371

Group type: EXPERIMENTAL
Intervention: Multiple arterial grafts
Number of subjects: 4300

Group type: COMPARATOR
Intervention: Single arterial graft (SAG)
Number of subjects: 4300
Study: 26058718

Group type: EXPERIMENTAL
Intervention: Transapical transcatheter aortic valve replacement (TA‐TAVR)
Number of subjects: 875

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 875
Study: 23883816

Group type: EXPERIMENTAL
Intervention: Synthetic bioabsorbable antibiotic-soaked nasal sponge in the middle meatus (MM)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Conventional postoperative oral antibiotic prophylaxis (1 week) and saline-soaked bioabsorbable MM sponge
Number of subjects: 321
Study: 21039936

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B at 3 mg kg(‐1) QD for 14 days, followed by 3 mg kg(‐1) QD
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B at 10 mg kg(‐1) QD for 14 days, followed by 3 mg kg(‐1) QD
Number of subjects: 201
Study: 19051066

Group type: EXPERIMENTAL
Intervention: Lovastatin (5 microM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lovastatin (20 microM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Basal octanoate oxidation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Muscle biopsy myopathy scores
Number of subjects: 18
Study: 17377982

Group type: EXPERIMENTAL
Intervention: Therapeutic apheresis
Number of subjects: 0
Study: 15252410

Group type: EXPERIMENTAL
Intervention: Home-based, low-to-moderate intensity exercise and education program
Number of subjects: 32

Group type: COMPARATOR
Intervention: Education only program
Number of subjects: 32
Study: 11422662

Group type: EXPERIMENTAL
Intervention: Kitavan males
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Kitavan females
Number of subjects: 387

Group type: COMPARATOR
Intervention: Swedish males
Number of subjects: 387

Group type: COMPARATOR
Intervention: Swedish females
Number of subjects: 387
Study: 9373044

Group type: EXPERIMENTAL
Intervention: AV nodal ablation and single- or dual-chamber pacemaker implantation
Number of subjects: 64
Study: 7837745

Group type: EXPERIMENTAL
Intervention: Spermatic index of toxicity measured using bull sperm cells in blood serum filtrate from patients with peritonitis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control glucose-nitrate solution
Number of subjects: 0
Study: 31515837

Group type: EXPERIMENTAL
Intervention: Surgical management (SX)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Non-surgical management (non-SX)
Number of subjects: 98
Study: 27901334

Group type: EXPERIMENTAL
Intervention: Methylcobalamin (MC)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both treatments (MC and ALA)
Number of subjects: 40
Study: 26285161

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study: 24708696

Group type: EXPERIMENTAL
Intervention: Continuous intraperitoneal insulin infusion (CIPII)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Subcutaneous (SC) therapy
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: CIPII
Number of subjects: 19
Study: 23043166

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 1030
Study: 19843296

Group type: EXPERIMENTAL
Intervention: Corticosteroid avoidance
Number of subjects: 197

Group type: COMPARATOR
Intervention: Corticosteroid maintenance
Number of subjects: 197
Study: 18661082

Group type: EXPERIMENTAL
Intervention: 3% mepivacaine hydrochloride injection
Number of subjects: 104

Group type: COMPARATOR
Intervention: 2% lidocaine with adrenaline
Number of subjects: 104
Study: 16450593

Group type: EXPERIMENTAL
Intervention: Adenosine (250 microg/kg) injected into the aortic root
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline injection
Number of subjects: 30
Study: 12598719

Group type: EXPERIMENTAL
Intervention: Bifidobacterium-administered group (oral administration of lyophilized bifidobacteria, Bifidobacterium breve M‐16V strain)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bifidobacterium-administered group
Number of subjects: 15
Study: 10469967

Group type: EXPERIMENTAL
Intervention: Skeletonized internal thoracic artery (group I, n = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Pedicled internal thoracic artery (group II, n = 12)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pedicled left internal thoracic artery
Number of subjects: 23
Study: 8693541

Group type: EXPERIMENTAL
Intervention: 5 mg OKT3
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2.5 mg OKT3
Number of subjects: 30
Study: 1657197

Group type: EXPERIMENTAL
Intervention: Combined treatment of alcoholics and drug addicts
Number of subjects: 450

Group type: COMPARATOR
Intervention: Separate treatment of alcoholics and drug addicts
Number of subjects: 450
Study: 7080887

Group type: EXPERIMENTAL
Intervention: Active person‐to‐person recruitment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal school publicity procedure
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Active person‐to‐person recruitment (subsequent application)
Number of subjects: 52
Study: 31841507

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (100,000 IU loading dose followed by 20,000 IU/week)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417
Study: 29030792

Group type: EXPERIMENTAL
Intervention: Identity Project intervention
Number of subjects: 215

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 215
Study: 27210845

Group type: EXPERIMENTAL
Intervention: Traditional Thai massage (TTM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study: 24786928

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX), etanercept, and rapidly tapered prednisolone (MEP)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Methotrexate (MTX) monotherapy
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Open-label MEP treatment
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: MEP (more aggressive therapy)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: American College of Rheumatology Pediatric 70 response at 4 months
Number of subjects: 85
Study: 22424948

Group type: EXPERIMENTAL
Intervention: Cycled parenteral nutrition (n = 34)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Continuous parenteral nutrition (n = 36)
Number of subjects: 70
Study: 21061393

Group type: EXPERIMENTAL
Intervention: 0.1% capsaicin cream
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 18930488

Group type: EXPERIMENTAL
Intervention: Adjuvant radiation therapy
Number of subjects: 431

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 431

Group type: COMPARATOR
Intervention: Seminal vesicle negative disease
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Seminal vesicle positive disease
Number of subjects: 431
Study: 15949199

Group type: EXPERIMENTAL
Intervention: Cling wrap (CW)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No cling wrap (NCW)
Number of subjects: 51
Study: 12078912

Group type: EXPERIMENTAL
Intervention: Two cycles of chemotherapy (CT) with (sub)total nodal irradiation (RT) as consolidation treatment.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Early intensive therapy including intensified cytoreductive CT and high-dose CT with autologous stem-cell transplantation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Four escalated BEACOPP followed by four baseline BEACOPP.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment of eight doxorubicin-bleomycin-vinblastine-dacarbazine.
Number of subjects: 0
Study: 10422928

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg/kg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg/kg after 2 min
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg after 2 min
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg/kg after 5 min
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg after 5 min
Number of subjects: 117

Group type: COMPARATOR
Intervention: Control (no neostigmine)
Number of subjects: 117
Study: 8524605

Group type: EXPERIMENTAL
Intervention: PCNA labelling
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MIB‐1 labelling
Number of subjects: 11
Study: 2255747

Group type: EXPERIMENTAL
Intervention: Naloxone (8 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 0
Study: 6996934

Group type: EXPERIMENTAL
Intervention: 10 mg dezocine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30169439

Group type: EXPERIMENTAL
Intervention: Cognitive Applications for Life Management (CALM)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Brain Health Training (Control)
Number of subjects: 224
Study: 29113731

Group type: EXPERIMENTAL
Intervention: Oral fexinidazole (1800 mg on days 1-4, 1200 mg on days 5-10)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Nifurtimox eflornithine combination therapy (15 mg/kg per day for 10 days, 400 mg/kg per day for 7 days)
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: Oral fexinidazole
Number of subjects: 394

Group type: COMPARATOR
Intervention: Nifurtimox eflornithine combination therapy
Number of subjects: 394
Study: 26987694

Group type: EXPERIMENTAL
Intervention: Single miniplate fixation with MMF (n=37)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Double miniplate fixation with MMF (n=59)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Double miniplate fixation without MMF (n=38)
Number of subjects: 134
Study: 24674974

Group type: EXPERIMENTAL
Intervention: Tailored counseling
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study: 23085245

Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg daily)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 20220537

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Exercise and Cimicifuga racemosa Group (EGCR)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 128
Study: 18977983

Group type: EXPERIMENTAL
Intervention: Combination therapy with desmopressin and extended-release anticholinergic medication
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 15848990

Group type: EXPERIMENTAL
Intervention: Lactobacilli-prepared tampons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo tampons
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermediate wet smear ratings according to Nugent's classification
Number of subjects: 0
Study: 12747444

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) chip
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sham chip placement
Number of subjects: 44
Study: 10902822

Group type: EXPERIMENTAL
Intervention: Peripheral vasodilatation measured by the ratio I/A of the maternal sphygmogram
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Glomerular filtration rate (GFR) measured with the in vitro radiofluorescent method
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cardiac output determined by the ejection angle from maternal carotid sphygmogram
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Extracellular volume measurement
Number of subjects: 11
Study: 8632337

Group type: EXPERIMENTAL
Intervention: Pindolol administration (10 mg twice daily) with NH4Cl (1.5 g every 6 hr)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control phase: Pindolol administration (10 mg twice daily) without NH4Cl
Number of subjects: 8
Study: 1313864

Group type: EXPERIMENTAL
Intervention: Formula plus gamma-linolenic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formula plus cholesterol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breast-fed infants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 0
Study: 2931247

Group type: EXPERIMENTAL
Intervention: EE/NG (ethinyl estradiol and levonorgestrel)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EE/DG (ethinyl estradiol and desogestrel)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EE/NG
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: EE/DG
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both EE/NG and EE/DG
Number of subjects: 11
Study: 31856001

Group type: EXPERIMENTAL
Intervention: Early and progressive mobility program with five levels of activity
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional treatment without a preestablished routine
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Early and progressive mobility program
Number of subjects: 99
Study: 30213095

Group type: EXPERIMENTAL
Intervention: Potassium citrate (30 mEq day‐1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27237964

Group type: EXPERIMENTAL
Intervention: Air Optix Aqua multifocal
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: PureVision 2 for Presbyopia
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Acuvue OASYS for Presbyopia
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Biofinity multifocal
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Monovision
Number of subjects: 35
Study: 24585474

Group type: EXPERIMENTAL
Intervention: Plastic models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Organ dissections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Virtual dissections
Number of subjects: 0
Study: 22461037

Group type: EXPERIMENTAL
Intervention: Live donor champion (LDC) intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 30
Study: 20576482

Group type: EXPERIMENTAL
Intervention: Exercise intervention (5 sessions of 45 min per week at 65-70% max HR for 4 menstrual cycles)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 391